In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective.
Key Points:
- FLAURA2 – studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets
- CHRYSALIS-2 – post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination with Lazertinib plus chemo
- MARS2 – when compared surgery followed by chemo vs chemo alone, chemo alone had better outcomes in patients with resectable mesothelioma
- EVOKE-02 – Sacituzumab approved bladder and breast cancer, was tested here along with Pembrolizumab in 1st line mNSCLC setting, with more data to come to confirm its arrival in this space
